REPL250117C22500
- 0.45
- 0.000.00%
Replimune Newsroom
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Express News | Replimune Group Inc - Primary Endpoints of Rp2-202 Study Are Overall Survival and Progression Free Survival
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Replimune Management to Meet With Jefferies
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)
Jefferies Maintains Buy on Replimune Group, Raises Price Target to $19
Replimune Group Analyst Ratings
Express News | Replimune Shares Extend Gains; Last up 8%
Express News | Replimune Group Inc - Amendment Reduces Atm Offering to $89 Mln
Express News | Replimune Group Inc - Co & Leerink Partners LLC Enters Amendment No. 2 to Sales Agreement
Reported Earlier, Replimune Prices $140M Upsized Public Offering Of 6,923,000 Common Shares At $13/Share
Replimune Expects Gross Proceeds From Offering to Be Approximately $140M>REPL
Replimune Announces Pricing of 6.9M Shares of Common Stock at $13.00 Each >REPL
Replimune Expects Offering to Close Nov. 27>REPL
Replimune Announces Pricing of Upsized Public Offering
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
Replimune Plans $125 Million Stock Sale, Net Proceeds to Fund Prospective Skin Cancer Treatment
Express News | Replimune Announces Proposed Public Offering
More Money In The Bank For Replimune Group Insiders Who Divested US$860k
Replimune REPL +35% BLA Submission; Omeros OMER +41% BLA Update